2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line

Celgene Corp. (NASDAQ:CELG) and bluebird bio (NASDAQ:BLUE) are frenemies. They're working together on a game-changing gene therapy for multiple myeloma, but they're also on a collision course in beta thalassemia, a common genetic disease.